Therion's course for HIV vaccine

By Karen Bernstein Editor-in-ChiefTherion Biologics Corp. has taken up the challenge of developing a live, attenuated HIV vaccine, although the research is more likely to result in other products than it is in the commercialization of a live vaccine.

Therion has exclusively licensed from Harvard Medical School technology developed by Ronald Desrosiers, based on HIV strains that have been weakened by the removal of the NEF gene and other genes. The company says the deletions mean that the virus can't spontaneously become virulent. ...